Our Commitment to Patients

Equillium is dedicated to finding new treatments to dramatically improve the lives of patients with diseases where treatment options are limited or not available. Our lead product candidate, itolizumab, has a novel mechanism that blocks key drivers of inflammation that lie at the root of many diseases.

Therapeutic Areas

Clinical Trials